# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Malignant fibrous histiocytoma

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-10 of 20 results.
Focused Ultrasound to Promote Immune Responses for Undifferentiated Pleomorphic Sarcoma
Status: Recruiting
Last Changed: Aug 10, 2020
First Received: Oct 11, 2019
Disease(s): Undifferentiated Pleomorphic Sarcoma
Intervention(s): ExAblate 2000/2100 Magnetic Resonance-guided Focused Ultrasound (MRgFUS)
Locations: University of California, San Francisco, San Francisco, California, United States
Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma
Status: Not yet recruiting
Last Changed: Jul 21, 2020
First Received: Jul 21, 2020
Disease(s): Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma
Intervention(s): Envafolimab, Ipilimumab
Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma
Status: Not yet recruiting
Last Changed: Jul 10, 2019
First Received: May 13, 2019
Disease(s): Soft Tissue Sarcomas, Undifferentiated Pleomorphic Sarcoma
Intervention(s): Anlotinib, Toripalimab, Blood Draw, Tumor Specimen Collection
Locations: First Hospital of Jilin University, Chang chun, Jilin, China
Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery
Status: Recruiting
Last Changed: Mar 04, 2020
First Received: Oct 12, 2017
Disease(s): Dedifferentiated Liposarcoma, Recurrent Dedifferentiated Liposarcoma, Recurrent Undifferentiated Pleomorphic Sarcoma, Resectable Dedifferentiated Liposarcoma, Resectable Undifferentiated Pleomorphic Sarcoma, Undifferentiated Pleomorphic Sarcoma
Intervention(s): Ipilimumab, Nivolumab, Radiation Therapy
Locations: M D Anderson Cancer Center, Houston, Texas, United States
Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma
Status: Recruiting
Last Changed: May 19, 2020
First Received: Apr 21, 2017
Disease(s): Sarcoma
Intervention(s): Pembrolizumab, Gemcitabine
Locations: Royal Marsden, London, United Kingdom
A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg
Status: Recruiting
Last Changed: Apr 09, 2020
First Received: Apr 03, 2020
Disease(s): Sarcoma, Myxofibrosarcoma, Undifferentiated Pleomorphic Sarcoma, Alveolar Soft Part Sarcoma
Intervention(s): Isolated Limb Infusion, Pembrolizumab, infusion of melphalan and dactinomycin
Locations: Memorial Sloan Kettering Cancer Center, New York, New York, United States
The Combination of Sintilimab and AI (Doxorubicin, ADM/Ifosfamide, IFO) for the First Line Treatment of Select Type of Metastatic/Unresectable Soft Tissue Sarcoma
Status: Recruiting
Last Changed: Jul 14, 2020
First Received: Apr 22, 2020
Disease(s): Sarcoma, Soft Tissue
Intervention(s): Sintilimab, Doxorubicin Hydrochloride, Ifosfamide
Locations: Fudan University, Cancer Hospital, Shanghai, Shanghai, China
A Study of Carilizumab in Combination With Apatinib in Subjects With Unresectable UPS and ASPS
Status: Not yet recruiting
Last Changed: Jun 25, 2020
First Received: Jun 25, 2020
Disease(s): Sarcoma
Intervention(s): Camrelizumab and Apatinib
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma
Status: Recruiting
Last Changed: Feb 19, 2020
First Received: Jun 16, 2017
Disease(s): Ewing Sarcoma, PEComa, Epithelioid Sarcoma, Desmoid Tumor, Chordoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Melanoma, Renal Cell Carcinoma, Squamous Cell Carcinoma, Hepatocellular Carcinoma, Classical Hodgkin Lymphoma, Colorectal Cancer, MTOR Activating Mutation
Intervention(s): Nab-Rapamycin, Nivolumab
Locations: Sarcoma Oncology Research Center, Santa Monica, California, United States
A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
Status: Recruiting
Last Changed: Jun 16, 2020
First Received: Apr 02, 2019
Disease(s): Sarcoma, Liposarcoma, Leiomyosarcoma, Undifferentiated Pleomorphic Sarcoma
Intervention(s): Eribulin, Pembrolizumab
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States